Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb (BMS) has taken over Amira Pharmaceuticals, a US based discoverer and early developer of new drugs to treat inflammatory and fibrotic diseases.
Subscribe to our email newsletter
Following the acquisition, Amira has become the wholly-owned subsidiary of BMS.
Earlier in July 2011, BMS signed a definitive agreement to acquire Amira for $325m.
The deal allowed BMS to take over Amira’s fibrosis program, including the lead asset AM152, which is now poised for Phase IIa proof-of-confidence studies for the treatment of idiopathic pulmonary fibrosis (IPF) and systemic Sclerosis (SSc), or scleroderma.